Lidoflazine
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.020.285 |
Chemical and physical data | |
Formula | C30H35F2N3O |
Molar mass | 491.627 g·mol−1 |
3D model (JSmol) | |
Melting point | 159 to 161 °C (318 to 322 °F) |
Solubility in water | Almost insoluble in water(<0.01%); Very soluble in chloroform(>50%); mg/mL (20 °C) |
| |
| |
(what is this?) (verify) |
Lidoflazine is a piperazine calcium channel blocker. It is a coronary vasodilator with some antiarrhythmic action.[1] Lidoflazine was discovered at Janssen Pharmaceutica in 1964.
Physical properties
[edit]Solubility at room temperature
[edit]Extracted from[1]
Solvent | 0.01 N | 0.1 N | ||
% | pH | % | pH | |
Hydrochloric Acid | 0.4 | 3.0 | 0.7 | 1.9 |
Tartaric Acid | 0.3 | 3.1 | 1.0 | 2.5 |
Citric Acid | 0.3 | 3.1 | 0.5 | 2.5 |
Lactic Acid | 0.2 | 3.4 | 0.7 | 2.9 |
Acetic Acid | 0.1 | 3.5 | 0.4 | 3.8 |
References
[edit]- ^ a b Schaper WK, Xhoneux R, Jageneau AH, Janssen PA (May 1966). "The cardiovascular pharmacology of lidoflazine, a long-acting coronary vasodilator". The Journal of Pharmacology and Experimental Therapeutics. 152 (2): 265–274. PMID 5944369.
Further reading
[edit]
- ^ Zhou PZ, Babcock J, Liu LQ, Li M, Gao ZB (June 2011). "Activation of human ether-a-go-go related gene (hERG) potassium channels by small molecules". Acta Pharmacologica Sinica. 32 (6): 781–788. doi:10.1038/aps.2011.70. PMC 4085723. PMID 21623390.